Subtype
Urinary System Carcinoma
CI-CAN-00004182Explore in graph →
670 active trials25 approved drugs87 evidence items
- NCIt
- C181197
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004182Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (391)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06940518 | Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07123090 | A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma(SPARCC) | recruiting | Phase 2 | 25 | Stephanie BergOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07187778 | Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE) | recruiting | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07714018 | Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance | recruiting | N/A | 20 | Roswell Park Cancer InstituteOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07776483 | Personalized ctDNA Monitoring for Predicting Immunotherapy Outcomes in Advanced Non-Clear Cell Renal Cell Carcinoma | not yet recruiting | — | 67 | West China HospitalOTHER | 0 | Aug 20, 2026 | clinicaltrials |
| NCT07776717 | TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma(TACTIC-RCC) | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 0 | Aug 20, 2026 | clinicaltrials |
| NCT04788095 | App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Cell Cancer | active not recruiting | N/A | 21 | City of Hope Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05361720 | Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study | recruiting | Phase 2 | 54 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | AstraZenecaINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06966024 | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | recruiting | Phase 1 | 60 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07097142 | Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study | recruiting | Phase 3 | 486 | NRG OncologyOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07160335 | A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors | active not recruiting | Phase 1 | 174 | Shanghai Henlius BiotechINDUSTRY | 4 | Aug 18, 2026 | clinicaltrials |
| NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | enrolling by invitation | Phase 3 | 5,000 | ExelixisINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT05776758 | Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt | active not recruiting | Phase 3 | 236 | Regina Elena Cancer InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06792552 | A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 738 | NextCure, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT07768306 | Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM | not yet recruiting | Phase 1 | 20 | Norroy Bioscience Co., LTDINDUSTRY | 0 | Aug 17, 2026 | clinicaltrials |
| NCT04736706 | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) | active not recruiting | Phase 3 | 1,854 | Merck Sharp & Dohme LLCINDUSTRY | 35 | Aug 14, 2026 | clinicaltrials |
| NCT05335941 | A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma | active not recruiting | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06284564 | A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) | active not recruiting | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07726602 | Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial | recruiting | — | 100 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07758881 | Evaluating the Safety and Performance of the Eight Medical Hyperthermia System IV 1.0 for HIVEC in NMIBC. | not yet recruiting | N/A | 30 | Eight Medical International BVINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT01038778 | Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer | active not recruiting | Phase 1 / Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02769962 | Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02830724 | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | recruiting | Phase 1 / Phase 2 | 124 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03782207 | A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice(IMreal) | completed | — | 2,756 | Hoffmann-La RocheINDUSTRY | 30 | Aug 13, 2026 | clinicaltrials |
| NCT05733715 | Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma | recruiting | Early Phase 1 | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06041503 | Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) | recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07763197 | Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)(SCORE-NMIBC) | recruiting | — | 400 | Natera, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05929235 | A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma | active not recruiting | Phase 1 | 120 | Flare Therapeutics Inc.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT03587662 | Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | completed | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04164082 | Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer | active not recruiting | Phase 2 | 161 | National Cancer Institute (NCI)NIH | 3 | Aug 11, 2026 | clinicaltrials |
| NCT04179162 | Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment | active not recruiting | Phase 1 / Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 270 | Lumara Bio Oncologics GmbHINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
| NCT06412848 | JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study | completed | — | 360 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06891209 | Exploration of HRQOL and Urinary Outcomes Following Partial Cystectomy | recruiting | — | 300 | Mayo ClinicOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07187869 | Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study | recruiting | Phase 1 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07195682 | A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | recruiting | Phase 1 | 281 | Bristol-Myers SquibbINDUSTRY | 5 | Aug 11, 2026 | clinicaltrials |
| NCT07239596 | Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom | recruiting | Phase 1 / Phase 2 | 92 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07615348 | CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk(PERFUMER-70) | recruiting | Phase 2 | 75 | Jinling Hospital, ChinaOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT01575548 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery | active not recruiting | Phase 3 | 129 | National Cancer Institute (NCI)NIH | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05805501 | A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma | active not recruiting | Phase 2 | 199 | Hoffmann-La RocheINDUSTRY | 9 | Aug 10, 2026 | clinicaltrials |
| NCT07756008 | Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer | not yet recruiting | Phase 2 / Phase 3 | 114 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07756437 | Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer(BLUT-DNA) | recruiting | — | 70 | AZ Sint-Lucas GentOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04752722 | LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | recruiting | Phase 1 / Phase 2 | 350 | enGene, Inc.INDUSTRY | 10 | Aug 7, 2026 | clinicaltrials |
| NCT05137262 | A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder | active not recruiting | Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07751796 | OptiCross HD IVUS for Assessing Invasion Depth in Upper Tract Urothelial Carcinoma | not yet recruiting | N/A | 15 | Yonsei UniversityOTHER | 0 | Aug 7, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 20, 2026source: clinicaltrials